|Day Low/High||235.15 / 240.47|
|52 Wk Low/High||184.50 / 279.98|
The most recent short interest data has been released for the 03/15/2017 settlement date, which shows a 5,524,975 share decrease in total short interest for Allergan PLC , to 8,520,757, a decrease of 39.34% since 02/28/2017. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded.
Shares of Allergan are gaining for the third straight session and, at midday, are trading above last week's high.
Stocks fall on Monday morning as Donald Trump's failure to push through health care reform raises doubts over his ability to enact other promised changes.
Paratek Pharmaceuticals soared while Foamix floundered ahead of market's open.
Doug Kass shares his thoughts on Twitter and talks about Sears.
Doug Kass shares his thoughts on Alphabet, Allergan and Ford.
With a 100-plus-year history, generous dividend, and diversified portfolio, could this Big Pharma player be resistant to Trump's drug price twitterstorm?
Brouhaha over GOP-led health-care deal is not really threatening the Republic. But you should have an investment plan in place.
Get your plan in place, but understand that the Republic is not in jeopardy.
First and Only Hyaluronic Acid (HA) Dermal Filler FDA Approved for the Correction of Moderate to Severe Wrinkles and Folds, such as Nasolabial Folds, That Lasts up to 18 Months(1,2*)
Fed's rate hike gives markets a midweek boost. In the portfolio, we trim 1 position and add to 3 others.
Jim Cramer says economic fundamentals remain strong and this market's rallying with relief at Fed's anticipated rate hike.
The deal announced Tuesday gives Allergan exclusive access to five Editas programs aimed at serious, inherited eye diseases.
Editas Medicine, Amphastar Pharmaceuticals, Aratana Therapeutics and Pacira Pharmaceuticals were among the biotech stock movers in premarket trading on Tuesday.
47% OF RESPONDENTS SAID THEY ARE BOTHERED BY THE APPEARANCE OF THE AREA UNDER THEIR CHIN(1)
Common Encourages Americans to Take Action When it Comes to Their Vision Care and Visit their Eye Doctor
Doug Kass shares his thoughts on Allergan, and says that Caterpillar remains purr-fect for shorting.
Doug Kass shares his thoughts on the state of the market, and notices that the irrational might now be rationalized.
After the jobs report, the markets look ahead to the Fed. In the portfolio, we exit a position while adding to 4 others.
Why the name is sagging, and what it will take to spur the sector higher.
To put it simply, Stanley Black & Decker and Thermo Fisher screwed up.
A firestorm in Washington has created a fire sale for shares of this undervalued stock.
- Application Seeks to Expand VRAYLAR Label to Include Phase 3 Clinical Data for the Maintenance Treatment of Schizophrenia-
Logitech CEO Bracken Darrell tells Jim Cramer that the cloud is the new growth platform for Logitech.
Jim Cramer is bullish on Arconic, Treehouse Foods, Magellan Midstream Partners.
Jim Cramer says if Trump really wants to lower drug prices, he should target our trading partners.
Tesla's slide doesn't spell doom for other carmakers and it might be a buying opportunity for some investors, says Jim Cramer.